CD30 expression in high-risk acute myeloid Leukemia and myelodysplastic syndromes

Wenli Zheng, L. Jeffrey Medeiros, Ying Hu, Linda Powers, Jorge E. Cortes, Farhad Ravandi-Kashani, Hagop H. Kantarjian, Sa A. Wang

Research output: Contribution to journalArticle

Abstract

Background: We assessed for CD30 expression in patients with acute myeloid leukemia (AML) or high-grade myelodysplastic syndrome (MDS) to examine the possibility that anti-CD30 could be targeted therapy in these patients. Methods: Multicolor flow cytometry immunophenotypic analysis was performed on bone marrow aspirates of 135 patients with AML or MDS and peripheral blood samples in a subset of 33 patients. Immunohistochemistry was performed on bone marrow aspirate clot specimens of 84 patients. Results: The median patient age was 63 years (range, 13-92 years); 102 (75%) patients had refractory or recurrent disease, and 68 (50%) had high-risk cytogenetics. Overall, the median percentage of blasts positive for CD30 was 14% (range, 0%-91%). By using an arbitrary 20% cutoff, 49 (36%) patients were considered to have CD30 expression. Monocytic cells, either mature or immature, were consistently negative for CD30. Therefore, CD30 expression was less in AML with monocytic differentiation (P =.006). The patients with persistent disease who had been actively treated had a higher level of CD30 expression than the patients who were untreated (P =.031). In paired samples, CD30 expression was consistently higher in bone marrow blasts than in peripheral blood blasts (P =.002). Immunohistochemistry demonstrated CD30 expression by myeloblasts in a subset of patients, but reactivity was generally weaker and focally compared. Conclusions: CD30 is expressed by myeloblasts in a substantial subset of patients with AML or MDS. Because the study group was composed mostly of patients with high-risk AML or MDS in whom very few treatment options are available, these data raise the possibility that anti-CD30-targeted therapy could be a potential option for this patient group.

Original languageEnglish (US)
Pages (from-to)307-314
Number of pages8
JournalClinical Lymphoma, Myeloma and Leukemia
Volume13
Issue number3
DOIs
StatePublished - Jun 1 2013
Externally publishedYes

Fingerprint

Myelodysplastic Syndromes
Acute Myeloid Leukemia
Granulocyte Precursor Cells
Bone Marrow
Immunohistochemistry
Cytogenetics
Flow Cytometry
Therapeutics

Keywords

  • Acute myeloid leukemia
  • CD30
  • Flow cytometry
  • Immunohistochemistry
  • Myelodysplastic syndromes

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

CD30 expression in high-risk acute myeloid Leukemia and myelodysplastic syndromes. / Zheng, Wenli; Medeiros, L. Jeffrey; Hu, Ying; Powers, Linda; Cortes, Jorge E.; Ravandi-Kashani, Farhad; Kantarjian, Hagop H.; Wang, Sa A.

In: Clinical Lymphoma, Myeloma and Leukemia, Vol. 13, No. 3, 01.06.2013, p. 307-314.

Research output: Contribution to journalArticle

Zheng, W, Medeiros, LJ, Hu, Y, Powers, L, Cortes, JE, Ravandi-Kashani, F, Kantarjian, HH & Wang, SA 2013, 'CD30 expression in high-risk acute myeloid Leukemia and myelodysplastic syndromes', Clinical Lymphoma, Myeloma and Leukemia, vol. 13, no. 3, pp. 307-314. https://doi.org/10.1016/j.clml.2012.12.006
Zheng, Wenli ; Medeiros, L. Jeffrey ; Hu, Ying ; Powers, Linda ; Cortes, Jorge E. ; Ravandi-Kashani, Farhad ; Kantarjian, Hagop H. ; Wang, Sa A. / CD30 expression in high-risk acute myeloid Leukemia and myelodysplastic syndromes. In: Clinical Lymphoma, Myeloma and Leukemia. 2013 ; Vol. 13, No. 3. pp. 307-314.
@article{6479add4d0c748b1918b38354bce8313,
title = "CD30 expression in high-risk acute myeloid Leukemia and myelodysplastic syndromes",
abstract = "Background: We assessed for CD30 expression in patients with acute myeloid leukemia (AML) or high-grade myelodysplastic syndrome (MDS) to examine the possibility that anti-CD30 could be targeted therapy in these patients. Methods: Multicolor flow cytometry immunophenotypic analysis was performed on bone marrow aspirates of 135 patients with AML or MDS and peripheral blood samples in a subset of 33 patients. Immunohistochemistry was performed on bone marrow aspirate clot specimens of 84 patients. Results: The median patient age was 63 years (range, 13-92 years); 102 (75{\%}) patients had refractory or recurrent disease, and 68 (50{\%}) had high-risk cytogenetics. Overall, the median percentage of blasts positive for CD30 was 14{\%} (range, 0{\%}-91{\%}). By using an arbitrary 20{\%} cutoff, 49 (36{\%}) patients were considered to have CD30 expression. Monocytic cells, either mature or immature, were consistently negative for CD30. Therefore, CD30 expression was less in AML with monocytic differentiation (P =.006). The patients with persistent disease who had been actively treated had a higher level of CD30 expression than the patients who were untreated (P =.031). In paired samples, CD30 expression was consistently higher in bone marrow blasts than in peripheral blood blasts (P =.002). Immunohistochemistry demonstrated CD30 expression by myeloblasts in a subset of patients, but reactivity was generally weaker and focally compared. Conclusions: CD30 is expressed by myeloblasts in a substantial subset of patients with AML or MDS. Because the study group was composed mostly of patients with high-risk AML or MDS in whom very few treatment options are available, these data raise the possibility that anti-CD30-targeted therapy could be a potential option for this patient group.",
keywords = "Acute myeloid leukemia, CD30, Flow cytometry, Immunohistochemistry, Myelodysplastic syndromes",
author = "Wenli Zheng and Medeiros, {L. Jeffrey} and Ying Hu and Linda Powers and Cortes, {Jorge E.} and Farhad Ravandi-Kashani and Kantarjian, {Hagop H.} and Wang, {Sa A.}",
year = "2013",
month = "6",
day = "1",
doi = "10.1016/j.clml.2012.12.006",
language = "English (US)",
volume = "13",
pages = "307--314",
journal = "Clinical Lymphoma, Myeloma and Leukemia",
issn = "2152-2650",
publisher = "Cancer Media Group",
number = "3",

}

TY - JOUR

T1 - CD30 expression in high-risk acute myeloid Leukemia and myelodysplastic syndromes

AU - Zheng, Wenli

AU - Medeiros, L. Jeffrey

AU - Hu, Ying

AU - Powers, Linda

AU - Cortes, Jorge E.

AU - Ravandi-Kashani, Farhad

AU - Kantarjian, Hagop H.

AU - Wang, Sa A.

PY - 2013/6/1

Y1 - 2013/6/1

N2 - Background: We assessed for CD30 expression in patients with acute myeloid leukemia (AML) or high-grade myelodysplastic syndrome (MDS) to examine the possibility that anti-CD30 could be targeted therapy in these patients. Methods: Multicolor flow cytometry immunophenotypic analysis was performed on bone marrow aspirates of 135 patients with AML or MDS and peripheral blood samples in a subset of 33 patients. Immunohistochemistry was performed on bone marrow aspirate clot specimens of 84 patients. Results: The median patient age was 63 years (range, 13-92 years); 102 (75%) patients had refractory or recurrent disease, and 68 (50%) had high-risk cytogenetics. Overall, the median percentage of blasts positive for CD30 was 14% (range, 0%-91%). By using an arbitrary 20% cutoff, 49 (36%) patients were considered to have CD30 expression. Monocytic cells, either mature or immature, were consistently negative for CD30. Therefore, CD30 expression was less in AML with monocytic differentiation (P =.006). The patients with persistent disease who had been actively treated had a higher level of CD30 expression than the patients who were untreated (P =.031). In paired samples, CD30 expression was consistently higher in bone marrow blasts than in peripheral blood blasts (P =.002). Immunohistochemistry demonstrated CD30 expression by myeloblasts in a subset of patients, but reactivity was generally weaker and focally compared. Conclusions: CD30 is expressed by myeloblasts in a substantial subset of patients with AML or MDS. Because the study group was composed mostly of patients with high-risk AML or MDS in whom very few treatment options are available, these data raise the possibility that anti-CD30-targeted therapy could be a potential option for this patient group.

AB - Background: We assessed for CD30 expression in patients with acute myeloid leukemia (AML) or high-grade myelodysplastic syndrome (MDS) to examine the possibility that anti-CD30 could be targeted therapy in these patients. Methods: Multicolor flow cytometry immunophenotypic analysis was performed on bone marrow aspirates of 135 patients with AML or MDS and peripheral blood samples in a subset of 33 patients. Immunohistochemistry was performed on bone marrow aspirate clot specimens of 84 patients. Results: The median patient age was 63 years (range, 13-92 years); 102 (75%) patients had refractory or recurrent disease, and 68 (50%) had high-risk cytogenetics. Overall, the median percentage of blasts positive for CD30 was 14% (range, 0%-91%). By using an arbitrary 20% cutoff, 49 (36%) patients were considered to have CD30 expression. Monocytic cells, either mature or immature, were consistently negative for CD30. Therefore, CD30 expression was less in AML with monocytic differentiation (P =.006). The patients with persistent disease who had been actively treated had a higher level of CD30 expression than the patients who were untreated (P =.031). In paired samples, CD30 expression was consistently higher in bone marrow blasts than in peripheral blood blasts (P =.002). Immunohistochemistry demonstrated CD30 expression by myeloblasts in a subset of patients, but reactivity was generally weaker and focally compared. Conclusions: CD30 is expressed by myeloblasts in a substantial subset of patients with AML or MDS. Because the study group was composed mostly of patients with high-risk AML or MDS in whom very few treatment options are available, these data raise the possibility that anti-CD30-targeted therapy could be a potential option for this patient group.

KW - Acute myeloid leukemia

KW - CD30

KW - Flow cytometry

KW - Immunohistochemistry

KW - Myelodysplastic syndromes

UR - http://www.scopus.com/inward/record.url?scp=84877760313&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84877760313&partnerID=8YFLogxK

U2 - 10.1016/j.clml.2012.12.006

DO - 10.1016/j.clml.2012.12.006

M3 - Article

C2 - 23313069

AN - SCOPUS:84877760313

VL - 13

SP - 307

EP - 314

JO - Clinical Lymphoma, Myeloma and Leukemia

JF - Clinical Lymphoma, Myeloma and Leukemia

SN - 2152-2650

IS - 3

ER -